The top after-market Nasdaq gainers Tuesday were Amicus Therapeutics Inc, Orexigen Therapeutics inc, Gevo Inc, Inter Parfums Inc and Complete Genomics Inc.
The top after-market Nasdaq losers were Rovi Corporation, Arena Pharmaceuticals Inc, VIVUS Inc SS&C Technologies Holdings Inc and Horizon Technology Finance Corporation.
Amicus Therapeutics Inc (FOLD) shares climbed 8.50 percent to $6.55 in after-hours trading Tuesday. Amicus Therapeutics Inc and Glaxo Group Limited (GSK) announced an expansion of their collaboration to develop and commercialize the investigational pharmacological chaperone migalastat HCl for Fabry disease.
Shares of Orexigen Therapeutics Inc (OREX) rose 6.44 percent in the post-market to close at $7.60. The biopharmaceutical company shares have a 52-week low of $1.22, a 52-week high of $7.73 and $483.93 million in market capitalization.
Gevo Inc (GEVO) shares advanced 4.47 percent to $4.67 in post-market trading. Gevo Inc. and Chemtex/TPG joint venture Beta Renewables announced Tuesday their collaboration to develop an integrated process for the production of bio-based isobutanol from cellulosic, non-food biomass.
Inter Parfums Inc (IPAR) shares gained 2.29 percent and reached $16.82 in after-hours trading. The company announced that since December 2011, Burberry and Inter Parfums subsidiary, InterparfumsSA, have been engaged in discussions on the creation of a new operating model for the business. Although an agreement has been reached on certain main terms and conditions, important points remain to be finalized, the company said in a statement.
Complete Genomics Inc (GNOM) shares surged 1.42 percent to $2.85 in after-hours trading Tuesday. The shares of the company have a 52-week low of $1.57, a 52-week high of $15.60 and $95.22 million in market capitalization.
Rovi Corporation (ROVI) shares slumped 24.65 percent to $13.30 in the post-market trading Tuesday. The company's shares went down by nearly a quarter after the company announced its preliminary second quarter results that reflected wider loss and lower revenues, falling short of market expectations.
The company reported an EPS of $0.35-$0.38, against the analysts' expectation of $0.57. The company revenues are in the range of $158-$179 million, versus the consensus estimate of $182.6 million.
Arena Pharmaceuticals Inc (ARNA) shares plunged 7.24 percent to $10.25 in the post-market trading. The shares of the company have a 52-week low of $1.23, a 52-week high of $13.50 and $2.02 billion in market capitalization.
VIVUS Inc (VVUS) shares lost 6.84 percent in after-hours trading to reach $24.65. The company shares showed volatility Tuesday, ahead of the U.S. Food and Drug Administration (FDA) approval for its weight-loss pill. The company announced later that it has acquired the FDA approval for Qsymia, as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related co-morbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia), reported Reuters.
SS&C Technologies Holdings Inc (SSNC) shares dropped 4.89 percent to $24.68 in after-hours trading. The company announced a public offering of its 7,000,000 shares common stock by investment funds affiliated with The Carlyle Group and the company will not receive any of the proceeds from the offering of shares by the selling stockholders.
Horizon Technology Finance Corporation (HRZN) shares declined 4.28 percent to $16.12 in after-hours trading. The company shares have a 52-week low of $12.24, a 52-week high of $17.31 and 127.89 million in market capitalization.